Journal of Clinical Oncology, Vol 10, 464-473, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose- intensive therapy

TC Shea, JR Mason, AM Storniolo, B Newton, M Breslin, M Mullen, DM Ward, L Miller, M Christian and R Taetle
Department of Medicine, University of California, San Diego.

PURPOSE: The trial was undertaken to study the effect of administering granulocyte-macrophage colony-stimulating factor (GM-CSF) with and without peripheral-blood progenitor cells (PBPC) on the hematologic and nonhematologic toxicity observed with multiple cycles of high-dose carboplatin chemotherapy. PATIENTS AND METHODS: Eighteen patients with a variety of solid tumors received a total of 40 cycles of carboplatin, 1,200 mg/m2 per cycle, administered by continuous infusion over 96 hours. All 40 courses were administered with a daily 4-hour intravenous (IV) infusion of either 5 or 10 micrograms/kg/d of recombinant human Escherichia coli-derived GM-CSF. The first 20 courses were administered without PBPC support (treatment A). Because of severe neutropenia and thrombocytopenia, the next 20 courses of therapy were administered with GM-CSF, PBPC, and oral antibiotic prophylaxis (treatment B). RESULTS: The addition of PBPC support led to a significant reduction in the duration of neutropenia (10.5 v 7.5 days; P = .027) and thrombocytopenia (12.4 v 5.2 days; P = .001), number of RBC transfusions (six v three; P = .01) and platelet transfusions (10.3 v 3.7; P = .013), number of hospital days (12.6 v 2.9; P = .01), and days of IV antibiotics (11.8 v 2.4; P = .007) per cycle. Significant increases in the weekly dose intensity (206 v 285 mg/m2/wk; P = .014) and total dose (2,287 v 3,600 mg/m2; P = .018) of carboplatin delivered were also observed with treatment B. The overall response rate in this study was 70%, with 11 of 16 assessable patients achieving either a complete (three patients) or partial (eight patients) remission. CONCLUSION: This combination of GM-CSF and PBPC infusion represents an effective method for delivering multiple cycles of high-dose carboplatin chemotherapy and may serve as a model for the administration of high-dose chemotherapy in future trials.

This article has been cited by other articles:

				A. Josting, M. Sieniawski, J.-P. Glossmann, O. Staak, L. Nogova, N. Peters, M. Mapara, B. Dorken, Y. Ko, B. Metzner, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study Ann. Onc., August 1, 2005; 16(8): 1359 - 1365. [Abstract] [Full Text] [PDF]

				A. Josting, C. Rudolph, M. Mapara, J.-P. Glossmann, M. Sienawski, M. Sieber, H. H. Kirchner, B. Dorken, D. K. Hossfeld, J. Kisro, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG) Ann. Onc., January 1, 2005; 16(1): 116 - 123. [Abstract] [Full Text] [PDF]

				D. Strother, D. Ashley, S. J. Kellie, A. Patel, D. Jones-Wallace, S. Thompson, R. Heideman, E. Benaim, R. Krance, L. Bowman, et al. Feasibility of Four Consecutive High-Dose Chemotherapy Cycles With Stem-Cell Rescue for Patients With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor After Craniospinal Radiotherapy: Results of a Collaborative Study J. Clin. Oncol., May 15, 2001; 19(10): 2696 - 2704. [Abstract] [Full Text] [PDF]

				M. E. Scheulen, R. A. Hilger, C. Oberhoff, J. Casper, M. Freund, K. M. Josten, M. Bornhauser, G. Ehninger, W. E. Berdel, J. Baumgart, et al. Clinical Phase I Dose Escalation and Pharmacokinetic Study of High-Dose Chemotherapy with Treosulfan and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Advanced Malignancies Clin. Cancer Res., November 1, 2000; 6(11): 4209 - 4216. [Abstract] [Full Text] [PDF]

				R. J. Schilder, S. Johnson, J. Gallo, S. Kindsfather, B. Rogers, M. A. Bookman, M. M. Millenson, M. Boente, N. Rosenblum, S. Litwin, et al. Phase I Trial of Multiple Cycles of High-Dose Chemotherapy Supported by Autologous Peripheral-Blood Stem Cells J. Clin. Oncol., July 1, 1999; 17(7): 2198 - 2198. [Abstract] [Full Text] [PDF]

				D. S. Alberts and R. T. Dorr New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors Oncologist, February 1, 1998; 3(1): 15 - 34. [Abstract] [Full Text]

				R. L. Basser, J. E.J. Rasko, K. Clarke, J. Cebon, M. D. Green, A. P. Grigg, J. Zalcberg, B. Cohen, J. O'Byrne, D. M. Menchaca, et al. Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer Blood, May 1, 1997; 89(9): 3118 - 3128. [Abstract] [Full Text] [PDF]

				S. A. Cannistra Cancer of the Ovary N. Engl. J. Med., November 18, 1993; 329(21): 1550 - 1559. [Full Text]

				J. W. Smith, D. L. Longo, W. G. Alvord, J. E. Janik, W. H. Sharfman, B. L. Gause, B. D. Curti, S. P. Creekmore, J. T. Holmlund, R. G. Fenton, et al. The Effects of Treatment with Interleukin-1{alpha} on Platelet Recovery after High-Dose Carboplatin N. Engl. J. Med., March 18, 1993; 328(11): 756 - 761. [Abstract] [Full Text]